Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Johan Lund has been appointed Chairman of the Board, bringing over 25 years of leadership in drug discovery and development from companies such as AstraZeneca and Pfizer. Karin Rosén also joins the Board, adding more than 20 years of global experience in clinical development and medical affairs from companies including Amgen (Horizon), GSK, Genentech (Roche) and Aimmune (Nestlé).
Johan Dighed, Helen Pettersson, David Kendall and Anthony Ford were re-elected to the Board. In line with general practice, CEO Per von Mentzer will also step down from his Board position.
The company’s Founder and Scientific Advisor Bengt von Mentzer stepped down from the Board as part of the renewal process and will continue to be closely involved in the scientific development of PN6047. In line with general practice, CEO Per von Mentzer will also step down from his Board position.
PharmNovo would like to thank Göran Lerenius, who has served as Chairman of the Board since 2017, for his valuable contributions and leadership during this period.
PharmNovo looks forward to working with the newly elected Board as the company continues its development and preparations for the next phase.
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Johan Lund has been appointed Chairman of the Board, bringing over 25 years of leadership in drug discovery and development from companies such as AstraZeneca and Pfizer. Karin Rosén also joins the Board, adding more than 20 years of global experience in clinical development and medical affairs from companies including Amgen (Horizon), GSK, Genentech (Roche) and Aimmune (Nestlé).
Johan Dighed, Helen Pettersson, David Kendall and Anthony Ford were re-elected to the Board. In line with general practice, CEO Per von Mentzer will also step down from his Board position.
The company’s Founder and Scientific Advisor Bengt von Mentzer stepped down from the Board as part of the renewal process and will continue to be closely involved in the scientific development of PN6047. In line with general practice, CEO Per von Mentzer will also step down from his Board position.
PharmNovo would like to thank Göran Lerenius, who has served as Chairman of the Board since 2017, for his valuable contributions and leadership during this period.
PharmNovo looks forward to working with the newly elected Board as the company continues its development and preparations for the next phase.
Latest news
View all
Reports of broader therapeutic potential for PN6047
PharmNovo AB announces today new preclinical findings supporting the potential of PN6047 in migraine and opioid withdrawal syndrome. The findings were generated through the company's NIDA-funded collaboration with researchers at Washington University School of Medicine.
Read more
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
